Zacks has identified biopharmaceutical company Kamada (KMDA) as a strong growth stock, assigning it a Growth Score of B and a Zacks Rank #2 (Buy). This recommendation is driven by a projected 57.3% EPS growth this year, significantly exceeding the industry average, an efficient asset utilization ratio of 0.46 compared to the industry's 0.31, and a 4.4% upward revision in current-year earnings estimates over the past month. These combined factors indicate Kamada is well-positioned for potential outperformance.
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. If you wish to go to ZacksTrade, click OK. If you do not, click Cancel. Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes" Read MoreHide Full Article Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all. By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. Our proprietary system currently recommends Kamada (KMDA - Free Report) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank 1 (Strong Buy) or 2 (Buy), returns are even better. Here are three of the most important factors that make the stock of this biopharmaceutical a great growth pick right now. Earnings Growth Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for Kamada is 0.9%, investors should actually focus on the projected growth. The company's EPS is expected to grow 57.3% this year, crushing the industry average, which calls for EPS growth of 18.3%. Impressive Asset Utilization Ratio Asset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric exhibits how efficiently a firm is utilizing its assets to generate sales. Right now, Kamada has an S/TA ratio of 0.46, which means that the company gets $0.46 in sales for each dollar in assets. Comparing this to the industry average of 0.31, it can be said that the company is more efficient. In addition to efficiency in generating sales, sales growth plays an important role. And Kamada looks attractive from a sales growth perspective as well. The company's sales are expected to grow 12.4% this year versus the industry average of 0%. Promising Earnings Estimate Revisions Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The current-year earnings estimates for Kamada have been revising upward. The Zacks Consensus Estimate for the current year has surged 4.4% over the past month. Bottom Line Kamada has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank 2 because of the positive earnings estimate revisions. This combination positions Kamada well for outperformance, so growth investors may want to bet on it. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Image: Bigstock Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes" Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all. By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. Our proprietary system currently recommends Kamada (KMDA - Free Report) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank 1 (Strong Buy) or 2 (Buy), returns are even better. Here are three of the most important factors that make the stock of this biopharmaceutical a great growth pick right now. Earnings Growth Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.While the historical EPS growth rate for Kamada is 0.9%, investors should actually focus on the projected growth. The company's EPS is expected to grow 57.3% this year, crushing the industry average, which calls for EPS growth of 18.3%. Impressive Asset Utilization Ratio Asset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.Right now, Kamada has an S/TA ratio of 0.46, which means that the company gets $0.46 in sales for each dollar in assets. Comparing this to the industry average of 0.31, it can be said that the company is more efficient. In addition to efficiency in generating sales, sales growth plays an important role. And Kamada looks attractive from a sales growth perspective as well. The company's sales are expected to grow 12.4% this year versus the industry average of 0%. Promising Earnings Estimate Revisions Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.The current-year earnings estimates for Kamada have been revising upward. The Zacks Consensus Estimate for the current year has surged 4.4% over the past month. Bottom Line Kamada has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank 2 because of the positive earnings estimate revisions.You can see the complete list of today's Zacks 1 Rank (Strong Buy) stocks here. This combination positions Kamada well for outperformance, so growth investors may want to bet on it. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Kamada (KMDA) presents a compelling growth profile based on forward-looking quantitative metrics. The biopharmaceutical company is projected to deliver earnings per share (EPS) growth of 57.3% this year, a figure that substantially exceeds the industry's average forecast of 18.3%. This earnings acceleration is supported by strong top-line expectations, with sales projected to increase by 12.4% against a flat (0%) industry average. Operationally, Kamada demonstrates superior efficiency, evidenced by a sales-to-total-assets (S/TA) ratio of 0.46, which indicates a more effective use of assets to generate revenue compared to the industry benchmark of 0.31. Reinforcing this positive outlook, analyst sentiment has been improving, with the Zacks Consensus Estimate for current-year earnings being revised upward by 4.4% over the past month. The combination of these factors has earned the stock a Zacks Rank 2 (Buy) and a Growth Score of B, signaling a strong potential for market outperformance according to the firm's model.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment
